Danaher is nearing a $10 billion acquisition of medical device maker Masimo, announced February 18, marking the largest healthcare deal of early 2026. The transaction caps a consolidation wave that accelerated after Q4 2025 sector valuations retreated from peak multiples.
Warner Bros. reopened acquisition discussions with Paramount on the same day, signaling media consolidation momentum alongside tech and healthcare. The talks follow Illumina's June 2025 SomaLogic acquisition and Broadcom's completed VMware deal, which reshaped enterprise software infrastructure.
CrowdStrike closed three acquisitions—Onum, Pangea, and an undisclosed third target—consolidating cybersecurity capabilities as enterprise security spending increased 18% year-over-year. NovacMPS acquired Tata Interactive Systems, extending consolidation into digital learning platforms.
Deal sizes range from mid-market tuck-ins to multi-billion transactions. Industry analysts tracking Q1 2026 volume against Q1 2025 report a 35% increase in announced healthcare deals and 22% growth in tech M&A by value. Premium-to-market multiples average 28% in healthcare and 24% in technology, below 2021-2022 peaks but above 2023-2024 averages.
Consolidation drivers include fragmented market structures, regulatory clarity on antitrust thresholds, and acquirer cash reserves exceeding $4 trillion across S&P 500 companies. Interest rate expectations shifted after February Federal Reserve guidance suggested potential cuts in Q3 2026, reducing debt financing costs for leveraged buyers.
Healthcare deals target diagnostics, medical devices, and digital health platforms where standalone companies face scaling challenges. Tech acquisitions focus on AI capabilities, cybersecurity, and cloud infrastructure as buyers seek vertical integration.
Completion rates for deals announced in Q4 2025 reached 78%, up from 68% in Q4 2024, indicating improved regulatory predictability. The Danaher-Masimo transaction awaits FTC review, expected by Q2 2026. Warner Bros.-Paramount faces Department of Justice scrutiny over media concentration concerns.
Sector valuations correlate with deal timing. Healthcare traded at 14.2x forward earnings in mid-February, below the 16.8x five-year average. Technology multiples compressed to 22.1x from 2021's 28.4x peak, creating entry points for strategic buyers and private equity firms deploying $890 billion in dry powder.